Inge Dierynck

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

Anthony Mills, Mark Nelson, Dushyantha Jayaweera et al. · AIDS · 2009 · 265 citations

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

James C. Sullivan, Sandra De Meyer, Doug J. Bartels et al. · Clinical Infectious Diseases · 2013 · 164 citations · Full text

Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier

Inge Dierynck, Mieke De Wit, Emmanuel Gustin et al. · Journal of Virology · 2007 · 157 citations · Full text

Immunology, Molecular Biology, Antiviral Drug +18

Potent inhibition of both human interferon-gamma production and biologic activity by the Clara cell protein CC16.

Inge Dierynck, A. Bernard, Harry A. Roels et al. · American Journal of Respiratory Cell and Molecular Biology · 1995 · 147 citations

Inflammatory Lung Disease, Lung Inflammation, Innate Immune System +20

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

Tara L. Kieffer, Sandra De Meyer, Doug J. Bartels et al. · PLoS ONE · 2012 · 87 citations · Full text